MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 2, 2006; DOI: 10.1124/mol.106.022301


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.022301v1
70/2/487    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CASSEL, S.
Right arrow Articles by ZWILLER, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CASSEL, S.
Right arrow Articles by ZWILLER, J.


Received for publication January 10, 2006.
Revised May 2, 2006.
Accepted for publication May 2, 2006.

Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain

Suzanne CASSEL 1, Delphine CAROUGE 2, Claire GENSBURGER 2, Patrick ANGLARD 2, Claude BURGUN 2, Jean-Bernard DIETRICH 2, Dominique AUNIS 2, Jean ZWILLER 3*

1 CNRS, FRE2855 2 Inserm U575, Centre de Neurochimie 3 Unite INSERM U575

* Address correspondence to: E-mail: zwiller{at}neurochem.u-strasbg.fr

Abstract

Once bound to methylated CpG sites, MeCP2 (methyl-CpG-binding protein 2) is thought to silence transcription of downstream genes by recruiting a histone deacetylase (HDAC). Mutations within the MeCP2 gene have been found to cause Rett syndrome, a disorder of arrested neuronal development. Using immunohistochemistry, we found that Mecp2, as well as the methyl-CpG-binding protein MBD1 were significantly induced in normal adult rat brain following repeated injections of fluoxetine or cocaine for ten days (1 injection/day). Mecp2 was not induced by repeated injections of GBR-12909 or nortriptyline. Together, the data indicate that the serotonergic system is predominantly involved. Using real time RT-PCR experiments, MBD1 mRNA and both Mecp2_e1 and Mecp2_e2 transcripts were found to be induced by fluoxetine. Induction of the methyl-binding proteins was accompanied with enhanced HDAC2 labeling intensity and mRNA synthesis in response to fluoxetine. Concomitantly, acetylated forms of histone H3 were found to be decreased. The effect was characterized in three serotonin projection areas, the caudate-putamen, the frontal cortex and the dentate gyrus subregion of hippocampus. Our data highlight GABAergic neurons as major target cells expressing Mecp2 in response to the serotonin-elevating agents and suggest that serotonin signaling enhances gene silencing in post-mitotic neurons.


Key words: Serotonin, DNA binding sites, Immunocytochemistry, Regulation of gene expression, Anti-depressants, Cocaine


This article has been cited by other articles:


Home page
J. Neurosci.Home page
P. Romieu, L. Host, S. Gobaille, G. Sandner, D. Aunis, and J. Zwiller
Histone Deacetylase Inhibitors Decrease Cocaine But Not Sucrose Self-Administration in Rats
J. Neurosci., September 17, 2008; 28(38): 9342 - 9348.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
A. K. Percy
Rett Syndrome: Recent Research Progress
J Child Neurol, May 1, 2008; 23(5): 543 - 549.
[Abstract] [PDF]


Home page
J. Neurosci.Home page
S. C. Pandey, R. Ugale, H. Zhang, L. Tang, and A. Prakash
Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism
J. Neurosci., April 2, 2008; 28(14): 3729 - 3737.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. S. Newton and R. S. Duman
Chromatin Remodeling: A Novel Mechanism of Psychotropic Drug Action
Mol. Pharmacol., August 1, 2006; 70(2): 440 - 443.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics